Clinical Study of Moxibustion Treatment of Renal Bone Disease Based on the Theory of Kidney Governing Bone

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082479

Enrollment

Unknown

Registered

2024-03-29

Start date

2024-04-01

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease–mineral and bone disorder (CKD-MBD)

Interventions

Observation group:Moxibustion

control group:Basic symptomatic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients with chronic kidney disease (CKD) stage 4-5 combined with renal bone disease; (2) Patients with deficiency of spleen-kidney Yang and stasis turbid block syndrome; (3) Age between 18-65; (4) Patients undergoing regular maintenance hemodialysis with more than 6 months course of hemodialysis; (5) No kidney transplantation, no malignant tumor, tuberculosis and other endocrine and consumable diseases, and the expected survival duration is more than 12 months; (6) Patients should understand the whole process of the experiment, volunteer to participate and sign the informed consent; (7) Patient has not participated in other clinical trials in recent 1 month.

Exclusion criteria

Exclusion criteria: (1) Patients may have other causes of bone diseases, such as climacteric syndrome, senile degenerative osteoarthritis, take medications that affect bone metabolism (Estrogen, long-term use of cortisol hormone) or have some other chronic diseases; (2) The normal development of bone is affected or caused by diseases; (3) Patients with chronic or active bleeding; (4) Patients with other serious organic diseases (such as tumors, etc.) (5) The disease was found during pregnancy, abortion and lactation; (6) Patients with mental illness; (7) Those who do not want to cooperate in this treatment.

Design outcomes

Primary

Measure	Time frame
Clinical Observation Form for Patients with Renal Bone Disease;Serum calcium, phosphorus, parathyroid hormone (PTH), alkaline phosphatase (ALP), 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], fibroblast growth factor 23 (FGF23), Klotho protein and Bone mineral density;	—

Secondary

Measure	Time frame
Bone Mineral Density (BMD);	—

Countries

China

Contacts

Public ContactYANG Guixian/HUANG Peidong

Yunnan University of Chinese Medicine

yeruyun@163.com+86 158 7795 8846

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026